# Efficacy and Safety of 12-weeks Supplementation of Eubacterium Hallii on Insulin Sensitivity and Glycaemic Control

> **NCT04529473** · NA · COMPLETED · sponsor: **Atlantia Food Clinical Trials** · enrollment: 100 (actual)

## Conditions studied

- Pre Diabetes
- Impaired Glucose Tolerance
- Insulin Sensitivity
- Insulin Resistance
- Glucose Metabolism Disorders
- Metabolic Syndrome

## Interventions

- **DIETARY_SUPPLEMENT:** Eubacterium hallii
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04529473
- **Lead sponsor:** Atlantia Food Clinical Trials
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-03
- **Primary completion:** 2022-08-23
- **Final completion:** 2022-08-23
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2022-11-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04529473

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04529473, "Efficacy and Safety of 12-weeks Supplementation of Eubacterium Hallii on Insulin Sensitivity and Glycaemic Control". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04529473. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*